PCM
ACHV icon

Perkins Capital Management’s Achieve Life Sciences ACHV Stock Holding History

Perkins Capital Management’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-125,212
Closed -$538K – 93
2023
Q3 		$538K Sell
125,212
-1,000
-0.8% -$5.04K 0.53% 52
2023
Q2 		$655K Sell
126,212
-11,000
-8% -$77.1K 0.57% 50
2023
Q1 		$933K Sell
137,212
-80,888
-37% -$384K 0.88% 42
2022
Q4 		$534K Hold
218,100
– – 0.56% 51
2022
Q3 		$720K Sell
218,100
-10,000
-4% -$47.7K 0.81% 40
2022
Q2 		$1.11M Buy
228,100
+53,500
+31% +$363K 1.15% 32
2022
Q1 		$1.32M Hold
174,600
– – 1.08% 37
2021
Q4 		$1.36M Buy
174,600
+5,000
+3% +$39.3K 0.92% 39
2021
Q3 		$1.44M Sell
169,600
-2,500
-1% -$19.6K 0.89% 39
2021
Q2 		$1.54M Buy
172,100
+131,500
+324% +$1.25M 0.88% 40
2021
Q1 		$470K Hold
40,600
– – 0.27% 78
2020
Q4 		$329K Buy
+40,600
New +$344K 0.22% 75

Other funds holding ACHV

SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Perkins Capital Management's ACHV Position: Q4 2023 in Review

Perkins Capital Management sold out of Achieve Life Sciences (ACHV) in Q4 2023, closing a stake of 125,212 shares — an estimated $538K sold.

Perkins Capital Management first reported a position in ACHV in Q4 2020 and held it in 12 quarters. The position peaked at $1.54M in Q2 2021. 30 funds tracked by Wall St. Rank hold ACHV as of Q4 2023.

  • Perkins Capital Management reported no remaining Achieve Life Sciences position as of Q4 2023 after selling out during the quarter.
  • Perkins Capital Management sold 125,212 Achieve Life Sciences shares in Q4 2023, an estimated $538K.
  • Perkins Capital Management first reported a position in Achieve Life Sciences in Q4 2020 and held it in 12 quarters.
  • Perkins Capital Management's Achieve Life Sciences position peaked at $1.54M in Q2 2021.
  • 30 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q4 2023.

Based on Perkins Capital Management's 13F filing for Q4 2023, filed 22 Jan 2024.